Core Viewpoint - The stock of Chongqing Dengkang Oral Care Products Co., Ltd. increased by 5.14% on February 2, reaching a price of 41.90 yuan per share, with a total market capitalization of 7.214 billion yuan [1] Company Overview - Chongqing Dengkang Oral Care Products Co., Ltd. was established on December 14, 2001, and went public on April 10, 2023. The company specializes in the research, production, and sales of oral care products [1] - The revenue composition of the company includes: adult toothpaste (80.43%), adult toothbrushes (9.90%), children's toothpaste (4.54%), oral medical and beauty care products (2.44%), children's toothbrushes (1.76%), electric toothbrushes (0.81%), and others (0.11%) [1] Shareholder Information - Huabao Fund's Huabao Kang Consumer Goods Mixed Fund (240001) is among the top ten circulating shareholders of Dengkang Oral Care. In the third quarter, the fund increased its holdings by 80,000 shares, totaling 780,000 shares, which represents 1.81% of the circulating shares [2] - The fund has achieved a floating profit of approximately 1.599 million yuan as of the latest data [2] Fund Performance - The fund manager of Huabao Kang Consumer Goods Mixed Fund is Tang Hui, who has been in the position for 6 years and 153 days. The fund's total asset size is 1.296 billion yuan [3] - During Tang Hui's tenure, the best fund return was 164.58%, while the worst return was -30.5% [3] Fund Holdings - In the fourth quarter, Huabao Kang Consumer Goods Mixed Fund reduced its holdings in Dengkang Oral Care by 380,000 shares, now holding 400,000 shares, which accounts for 2.09% of the fund's net value [4] - The fund has a floating profit of approximately 820,000 yuan from its current holdings in Dengkang Oral Care [4]

Group 1 - The core point of the news is that Chengdu Dengkang Oral Care Products Co., Ltd. has seen a stock price increase of 5.18%, reaching 40.22 CNY per share, with a total market capitalization of 6.925 billion CNY as of January 13 [1] - The company, established on December 14, 2001, specializes in the research, production, and sales of oral care products, with its main revenue sources being adult toothpaste (80.43%), adult toothbrushes (9.90%), and children's toothpaste (4.54%) [1] - The trading volume for the stock was 88.909 million CNY, with a turnover rate of 5.25% [1] Group 2 - Silver Hua Fund has a significant holding in Dengkang Oral Care, with the Silver Hua Yongxiang Flexible Allocation Mixed Fund (180028) holding 61,200 shares, representing 2.51% of the fund's net value [2] - The fund has generated a floating profit of approximately 121,200 CNY today, with a total fund size of 92.028 million CNY [2] - Year-to-date, the fund has achieved a return of 6.79%, ranking 2178 out of 8836 in its category, and a one-year return of 25.9%, ranking 4989 out of 8091 [2]

Core Viewpoint - The stock of Dengkang Oral Care has shown a year-to-date increase of 15.93%, with recent fluctuations indicating a slight decline in the short term, while the company continues to report growth in revenue and net profit [1][2]. Company Overview - Dengkang Oral Care, established on December 14, 2001, and listed on April 10, 2023, is based in Chongqing and specializes in the research, production, and sales of oral care products [1]. - The company's main revenue sources include adult toothpaste (80.43%), adult toothbrushes (9.90%), children's toothpaste (4.54%), and other oral care products [1]. Financial Performance - For the period from January to September 2025, Dengkang Oral Care achieved a revenue of 1.228 billion yuan, representing a year-on-year growth of 16.66%, and a net profit attributable to shareholders of 136 million yuan, up 15.21% year-on-year [1][2]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 8.38% to 10,600, with an average of 4,069 circulating shares per person, a decrease of 7.73% [1]. - The company has distributed a total of 344 million yuan in dividends since its A-share listing [2]. Institutional Holdings - The top circulating shareholder is Tianhong Yongli Bond A, holding 1.4526 million shares, followed by Xin'ao Quality Return Mixed Fund, which reduced its holdings by 67,400 shares [2]. - Other notable shareholders include Fuguo Consumption Theme Mixed A and Huabao Kang Consumer Products Mixed Fund, with varying changes in their holdings [2].

Core Viewpoint - The company, Dengkang Oral Care, has shown a mixed performance in terms of financing activities and stockholder dynamics, with a notable increase in revenue and net profit year-on-year, indicating growth potential in the oral care market [1][2]. Financing Activities - On October 30, Dengkang Oral Care's stock price fell by 2.20%, with a trading volume of 65.24 million yuan. The financing buy-in amounted to 4.29 million yuan, while the financing repayment was 8.35 million yuan, resulting in a net financing outflow of 4.06 million yuan [1]. - As of October 30, the total financing and securities lending balance for Dengkang Oral Care was 40.99 million yuan, which represents 2.55% of its market capitalization. This financing balance is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - The company had no securities lending activity on October 30, with a securities lending balance of 0.00 shares, which is below the 30th percentile of the past year, indicating low borrowing activity [1]. Financial Performance - For the period from January to September 2025, Dengkang Oral Care reported a revenue of 1.228 billion yuan, reflecting a year-on-year growth of 16.66%. The net profit attributable to shareholders was 136 million yuan, marking a 15.21% increase compared to the previous year [2]. - Since its A-share listing, Dengkang Oral Care has distributed a total of 344 million yuan in dividends [3]. Shareholder Dynamics - As of September 30, 2025, the number of shareholders for Dengkang Oral Care reached 10,600, an increase of 8.38% from the previous period. The average number of circulating shares per shareholder decreased by 7.73% to 4,069 shares [2]. - The top circulating shareholders include Tianhong Yongli Bond A, which holds 1.4526 million shares as the largest shareholder, and several other funds with varying changes in their holdings [3].

Core Viewpoint - Dengkang Oral Care, a well-known company in the domestic oral care industry, focuses on the research, production, and sales of oral care products, leveraging strong technical expertise and a complete industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Dengkang Oral Care reported revenue of 1.228 billion yuan, ranking 2nd in the industry, surpassing the industry average of 1.1 billion yuan and the median of 1.174 billion yuan [2] - The company's net profit for the same period was 136 million yuan, also ranking 2nd in the industry, exceeding the industry average of 127 million yuan and the median of 109 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Dengkang Oral Care's debt-to-asset ratio was 26.41%, slightly lower than the previous year's 27.66% but still above the industry average of 25.71% [3] - The gross profit margin for the same period was 50.50%, an increase from 49.25% year-on-year, and higher than the industry average of 37.91% [3] Group 3: Executive Compensation - The chairman, Deng Rong, received a salary of 1.6126 million yuan in 2024, an increase of 138,500 yuan from 2023 [4] - The general manager, Zhao Fengshuo, also received a salary of 1.6126 million yuan in 2024, reflecting the same increase as the chairman [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 8.38% to 10,600, with an average holding of 4,069.54 shares, a decrease of 7.73% from the previous period [5] - New shareholders include Tianhong Yongli Bond A and Xingye Xingrui Two-Year Holding Period Mixed A, while some existing shareholders reduced their holdings [5] Group 5: Future Outlook - According to招商证券, Dengkang Oral Care is expected to achieve net profits of 202 million yuan, 253 million yuan, and 322 million yuan for 2025-2027, with corresponding P/E ratios of 33.3, 26.5, and 20.9 [5] - 长江证券 forecasts net profits of 189 million yuan, 243 million yuan, and 305 million yuan for the same period, with P/E ratios of 36, 28, and 22 [6]

Company Overview - Chongqing Dengkang Oral Care Products Co., Ltd. is located at 389 Haier Road, Jiangbei District, Chongqing, established on December 14, 2001, and listed on April 10, 2023 [1] - The company specializes in the research, production, and sales of oral care products [1] Revenue Composition - The main revenue sources are: Adult toothpaste 80.43%, Adult toothbrush 9.90%, Children's toothpaste 4.54%, Oral medical and beauty care products 2.44%, Children's toothbrush 1.76%, Electric toothbrush 0.81%, Other (supplement) 0.11% [1] Stock Performance - On September 4, Dengkang Oral Care's stock rose by 5.18%, trading at 42.65 yuan per share, with a transaction volume of 1.08 billion yuan and a turnover rate of 6.05%, resulting in a total market capitalization of 7.343 billion yuan [1] Fund Holdings - Dengkang Oral Care is a significant holding in the Zhonghai Consumption Mixed A Fund (398061), which increased its holdings by 15,400 shares in the second quarter, totaling 212,000 shares, representing 4.64% of the fund's net value [2] - The fund has achieved a floating profit of approximately 445,200 yuan as of the latest report [2] Fund Manager Performance - The fund manager, He Wenyin, has been in position for 3 years and 203 days, with the fund's total asset size at 303 million yuan [3] - During his tenure, the best fund return was 28.32%, while the worst was -32.34% [3]

Group 1 - The core viewpoint of the news is the performance and market position of Chongqing Dengkang Oral Care Products Co., Ltd, which saw a stock price increase of 5.18% to 42.65 CNY per share, with a total market capitalization of 7.343 billion CNY [1] - The company was established on December 14, 2001, and went public on April 10, 2023, focusing on the research, production, and sales of oral care products [1] - The revenue composition of the company includes adult toothpaste (80.43%), adult toothbrushes (9.90%), children's toothpaste (4.54%), oral medical and beauty care products (2.44%), children's toothbrushes (1.76%), electric toothbrushes (0.81%), and other products (0.11%) [1] Group 2 - From the perspective of fund holdings, Dengkang Oral Care is a significant investment for Nanhua Fund, with its Nanhua Ruiying Mixed Fund A holding 24,200 shares, accounting for 3.32% of the fund's net value, ranking as the sixth-largest holding [2] - The Nanhua Ruiying Mixed Fund A was established on August 16, 2017, with a current scale of 24.0118 million CNY, and has achieved a year-to-date return of 1.01% [2] - The fund's one-year return is 28.8%, ranking 4635 out of 7978 in its category, and since inception, it has returned 35.6% [2] Group 3 - The fund manager of Nanhua Ruiying Mixed Fund A is Xu Chao, who has been in the position for 9 years and 308 days, with a total asset scale of 650 million CNY [3] - Xu Chao's best fund return during his tenure is 129.63%, while the worst return is -18.74% [3] - The co-manager, Lu Yue, has been in the role for 1 year and 50 days, managing assets of 35.5714 million CNY, with a best return of 30.62% and a worst return of 29.78% during his tenure [3]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [7] Core Views - The company achieved a revenue of 840 million yuan in H1 2025, representing a year-on-year increase of 19.7%, and a net profit attributable to shareholders of 90 million yuan, up 17.6% year-on-year [1] - The online channel continues to drive growth, with e-commerce revenue reaching 300 million yuan in H1 2025, a significant increase of 86.9% year-on-year, while offline revenue remained stable at 540 million yuan, down 0.2% year-on-year [2] - The company is focusing on new product launches, particularly in the medical research category, which is expected to enhance growth and optimize product structure [4] - The company is the absolute leader in the sensitive toothpaste market, with strong growth potential through product upgrades and market expansion [5] Financial Performance Summary - In H1 2025, the gross margin was 52.6%, an increase of 5.7 percentage points year-on-year, while the net profit margin was 10.1%, a slight decrease of 0.18 percentage points year-on-year [3] - The company forecasts revenues of 1.863 billion yuan, 2.191 billion yuan, and 2.574 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 196 million yuan, 235 million yuan, and 282 million yuan [12]

Core Viewpoint - The company reported a strong performance in the first half of 2025, with revenue and net profit showing significant year-on-year growth, indicating a positive outlook for the business. Financial Performance - In H1 2025, the company achieved revenue of 842 million, a year-on-year increase of 19.7%, and a net profit attributable to shareholders of 85 million, up 17.6% [1] - Q2 2025 revenue reached 411 million, reflecting a 20.1% increase year-on-year, with net profit of 42 million, a 19.7% increase [1] - The company's net profit margin for H1 2025 was 10.12%, a slight decrease of 0.18 percentage points year-on-year [3] Revenue Breakdown - Adult toothpaste, which accounted for 80% of total revenue, saw a 23% increase in revenue [2] - Emerging oral care products generated revenue of 20 million, growing by 54.85% [2] - Electric toothbrush sales reached 6.816 million, a year-on-year increase of 37.33% [2] - E-commerce channel revenue surged to 325 million, a significant growth of 81.13%, increasing its share of total revenue from 25.53% to 38.62% [2] - Offline channel revenue was 517 million, showing a slight decline of 1.3% [2] Cost Structure and Profitability - The gross margin for H1 2025 was 52.61%, an increase of 5.68 percentage points year-on-year [3] - The sales expense ratio rose to 36.5%, up 6.3 percentage points, primarily due to increased investment in e-commerce and product upgrades [3] - Management, R&D, and financial expense ratios were 3.38%, 3.1%, and -0.7%, respectively, with management and R&D expenses decreasing year-on-year [3] Investment Outlook - The company maintains a stable offline channel while driving rapid growth in online channels through high-margin products [4] - The projected net profits for 2025-2027 are 204 million, 246 million, and 293 million, with year-on-year growth rates of 26.7%, 20.3%, and 19.4% respectively [4] - The current valuation corresponds to multiples of 37x, 31x, and 26x for the respective years [4]

Macro and Strategy - The equity market is currently in an accelerating upward phase, prompting discussions on how to adjust positions to prepare for potential market fluctuations [8] - Investors are advised to consider right-side position reduction as a more reasonable choice, given the current market dynamics [8] - Historical data suggests that low-priced convertible bonds (priced between 110-115 yuan) tend to be more resilient during market downturns [8] Company and Industry Analysis - **Dengkang Dental (001328.SZ)**: The company reported a stable growth in Q2 2025, with revenue reaching 842 million yuan, a year-on-year increase of 19.72%, and a net profit of 85 million yuan, up 17.59% [10][11] - **Marubi Biotechnology (603983.SH)**: The company achieved a revenue of 1.769 billion yuan in H1 2025, a 30.83% increase year-on-year, while net profit grew by 5.21% to 186 million yuan [13][14] - **Haidi Lao (06862.HK)**: The company reported a revenue of 20.7 billion yuan in H1 2025, a decrease of 3.7%, with core operating profit down 14% [17][18] - **Green Tea Group (06831.HK)**: The company achieved a revenue of 2.29 billion yuan in H1 2025, a 23.1% increase, with adjusted net profit rising by 40% [19][20] - **Haisco Pharmaceutical (002653.SZ)**: The company reported a revenue of 2 billion yuan in H1 2025, an 18.6% increase, with anesthetic product revenue growing by 54% [22][23] - **Furui Co., Ltd. (300049.SZ)**: The company achieved a revenue of 713 million yuan in H1 2025, an 11.02% increase, while net profit was impacted by foreign exchange losses [26][27] - **Kaili Medical (300633.SZ)**: The company reported a revenue of 964 million yuan in H1 2025, a decrease of 4.78%, with net profit down 72.43% due to high initial investments in new product lines [29][30] - **Yuyue Medical (002223.SZ)**: The company reported a revenue of 4.659 billion yuan in H1 2025, an 8.2% increase, with net profit rising by 7.4% [31][32]